• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Launches Welch Allyn Connex 360 Vital Signs Monitor to Advance Connected Patient Monitoring

    9/16/25 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    • Designed for optimized workflows to support earlier detection of patient deterioration
    • Future-ready device features customizable configurations and upgrade capabilities
    • Connects to Baxter's cloud-based platform DeviceBridge, helping to enable quick, secure transfer of vital signs data to electronic medical records

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter's connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital's clinical routines, and upgrade capabilities that set the stage for future functionality and enhancements. With automated clinical documentation, Connex 360 is designed to simplify the clinician experience and allow more time to focus on patients.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916273572/en/

    Baxter's Welch Allyn Connex 360 Vital Signs Monitor

    Baxter's Welch Allyn Connex 360 Vital Signs Monitor

    "There is nothing more important than keeping patients safe, especially when time is of the essence," said Julie Foster, president of Front Line Care at Baxter. "Care teams rely on vital signs monitoring to help detect changes in their patients' conditions and make informed decisions. With Connex 360, we are advancing patient monitoring to provide care teams with the timely insights they need at the bedside, so they can make the most of every moment with their patients."

    In today's complex healthcare environment, care teams and hospital staff are being asked to do more with less, and timely, accurate, and secure patient information is critical. Baxter's Connex 360 monitor captures vital signs for adult, pediatric and neonate patients, including blood pressure, temperature, pulse rate, respiration rate1 and blood oxygen levels.2 Designed for optimized workflows, care teams can obtain a full set of patient vitals in less than one minute and automatically send to the electronic medical record, helping to reduce manual data entry errors and support informed care decisions.

    This secure data flow is powered by Baxter's cloud-based DeviceBridge platform, which works behind the scenes to help enable accurate data transfer from Connex 360 to hospital IT systems, including the EMR. DeviceBridge also helps support secure device access and clinical data interoperability across Baxter's ecosystem of connected devices.

    Additional key features of Connex 360 include:

    • Comprehensive security: Enhanced security features, including end-to-end encryption and certificate-based authentication, help protect patient and facility information.
    • Intuitive interface: Baxter's largest and most responsive color touchscreen allows intuitive navigation and the ability to see more patient data on one screen.
    • Enhanced customization: Customizable Early Warning Score protocols alert clinicians to patient deterioration or changes in condition, and fully configurable monitoring modes support the individual needs of the patient.
    • Easy upgrades and maintenance: Software upgrades for clinical, operational, and cybersecurity enhancements are streamlined, helping to reduce the burden on hospital IT teams and allowing for enhanced functionality over time.

    Baxter expanded its presence in the patient monitoring space through its acquisition of Hillrom and the Welch Allyn portfolio. Welch Allyn has a longstanding history of delivering innovative patient monitoring solutions that support patient care across healthcare settings, from hospitals to outpatient care. Baxter has continued to invest in connected monitoring, with Connex 360 joining the company's trusted lineup of vital signs solutions. The Connex 360 monitor received U.S. Food and Drug Administration 510(k) clearance and is now available for hospitals and health systems to order in the U.S. Learn more here.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    Rx Only. For safe and proper use of the product mentioned herein, please refer to the appropriate Operator's Manual or Instructions for Use.

    This release includes forward-looking statements concerning potential benefits associated with Welch Allyn Connex 360 and DeviceBridge. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

    Baxter, Connex 360, DeviceBridge, Hillrom and Welch Allyn are trademarks of Baxter International Inc.

    1 Digitally measure respiration rate with Masimo RRp, for patients greater than two years old.

    2 For a system configured with the Masimo SpO2 module and the SpO2 sensor RRp measurement option, the noninvasive measurement of Respiration Rate is not intended to be used for neonatal/infant patients.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250916273572/en/

    Media Contact

    Natalie Matthews, (224) 948-5353

    [email protected]



    Investor Contact

    [email protected]

    Get the next $BAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    5/10/2024$40.00Buy → Hold
    TD Cowen
    More analyst ratings

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Launches Welch Allyn Connex 360 Vital Signs Monitor to Advance Connected Patient Monitoring

    Designed for optimized workflows to support earlier detection of patient deterioration Future-ready device features customizable configurations and upgrade capabilities Connects to Baxter's cloud-based platform DeviceBridge, helping to enable quick, secure transfer of vital signs data to electronic medical records Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter's connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital's clinic

    9/16/25 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Reports Second-Quarter 2025 Results

    Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

    7/31/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

    7/17/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Baxter with a new price target

    Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

    2/26/25 7:01:30 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP,Group President,Pharma Sonig Alok covered exercise/tax liability with 3,191 shares, decreasing direct ownership by 2% to 128,219 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:02:32 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President and CEO Hider Andrew P. was granted 368,050 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and CFO Grade Joel T. was granted 102,712 shares, increasing direct ownership by 86% to 222,560 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    9/4/25 6:01:18 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    SEC Form 10-Q filed by Baxter International Inc.

    10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    8/5/25 4:48:23 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    7/31/25 7:18:36 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    7/7/25 8:51:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports Second-Quarter 2025 Results

    Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

    7/31/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

    7/17/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Declares Quarterly Dividend

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on October 1, 2025, to stockholders of record as of August 29, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched po

    7/14/25 4:40:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities